Real-World (RW) Observations from CAR T in R/R Myeloma
The panelist discusses how real-world evidence for CAR T in relapsed/refractory multiple myeloma shows promising efficacy but with some differences from clinical trials. Ide-cel demonstrates effectiveness in patients with prior BCMA exposure, though responses may be impacted. Compared with standard of care (SOC), both ide-cel and cilta-cel show superior outcomes in terms of response rates and progression-free survival, though long-term data are still emerging in real-world settings.
Video content above is prompted by the following:
- Briefly comment on real-world (RW) evidence surrounding the use of CAR T for R/R MM.
- RW ide-cel and prior BCMA exposure
- SOC comparison, ide-cel and cilta-cel
Gasparetto Explains Rationale for Quadruplet Front Line in Transplant-Ineligible Myeloma
February 22nd 2025In a Community Case Forum in partnership with the North Carolina Oncology Association, Cristina Gasparetto, MD, discussed the CEPHEUS, IMROZ, and BENEFIT trials of treatment for transplant-ineligible newly diagnosed multiple myeloma.
Read More
